REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). Operating from its Beltsville, Maryland facility,...
“Invisible millions” with hearing loss missing from mainstream media
New global research reveals a major media blind spot: Many people are unable to recall seeing anyone wearing a hearing device or hearing aid in mainstream content not related to hearing loss. To mark World Hearing Day, GN launches New Norm vol. 2: Free global library of authentic images showcases real people with hearing loss. BALLERUP, Denmark,...
Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understanding (MOU) with CellType, an AI-driven biotech company backed by...
Rosti Asia 2025 Review & 2026 Outlook: Building on Shared Success
SINGAPORE, March 3, 2026 /PRNewswire/ -- A report from Ringiertrade. Pat Williams, Senior Vice President of Rosti Asia, writes how Rosti Asia has performed strongly across its markets in 2025 despite challenges, as it looks forward to new opportunities in 2026. 2025 was a year of resilience, collaboration, and meaningful progress for Rosti Asia. Guided by our core...
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) management Hong Kong will serve as Hua Medicine's launchpad for international market expansion SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ -- Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA)...
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma’s Global Platform
NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment...
Bright Eye Clinic Achieves Government Accreditation Amid Korea’s Medical Tourism Growth
SEOUL, South Korea, March 3, 2026 /PRNewswire/ -- Bright Eye Clinic announced its official accreditation under the Korean Accreditation Program for Hospitals Serving Foreign Patients (KAHF), administered by the Korea Health Industry Development Institute (KHIDI) under the Ministry of Health and Welfare. The accreditation is valid from April 25, 2025 to April 24, 2029, making Bright Eye Clinic the only...
Efor strengthens its presence in Asia with the acquisition of No deviation
LYON, France, March 3, 2026 /PRNewswire/ -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, announces the acquisition of Singapore-based No deviation, a company recognized for its expertise in Commissioning, Qualification & Validation (CQV), Computer System Validation (CSV), Quality Compliance and Digital Enablement. Founded in...
US BioTek Laboratories Completes Merger With NutriPATH Pathology
SEATTLE and MELBOURNE, Australia, March 3, 2026 /PRNewswire/ -- US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology laboratory serving integrative and functional medicine practitioners. The merger marks a significant milestone for the...
Skyhawk Announces Australia’s Therapeutic Goods Administration Has Determined SKY-0515 for Huntington’s Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for registration via the provisional approval pathway. Skyhawk delivered its application for provisional approval to the TGA today. More than 115 patients are now...
